Abstract: The present invention relates to a composition comprising extract of the plant Ficus arnottiana. The invention also relates to a process for the preparation of the composition and to the composition for the use in the treatment of viral infections, particularly caused by herpes simplex viruses (HSV). The invention further relates to a method of treating a viral infection in a mammal comprising administering to the mammal a therapeutically effective amount of the composition.

Abstract: The present invention relates to a herbal composition comprising a therapeutically effective amount of an extract of the plant Terminalia elliptica as an active ingredient and optionally, a pharmaceutically acceptable carrier. The invention also relates to a process for the preparation of the extract. The invention also relates to a method for the treatment of metabolic disorders using the composition. The present invention also relates to a composition comprising a therapeutically effective amount of an extract of the plant Terminalia elliptica for use in combination with one or more further therapeutically active agent for the treatment of metabolic disorders.

Abstract: The present invention relates to a composition comprising extract of the plant Ficus arnottiana. The invention also relates to a process for the preparation of the composition and to the composition for the use in the treatment of viral infections, particularly caused by herpes simplex viruses (HSV). The invention further relates to a method of treating a viral infection in a mammal comprising administering to the mammal a therapeutically effective amount of the composition.

Abstract: The invention provides a novel benzoxazepine compound of the general formula (I): wherein R1 and R2 are as defined in the specification; or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith.

Abstract: This invention relates to a novel purified compound PM181104, of formula: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.

Abstract: The invention provides a novel benzoxazepine compound of the general formula (I): wherein R1 and R2 are as defined in the specification; or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof; a process for its preparation; and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith.

Abstract: This invention relates to a novel purified compound PM181104, of formula: of molecular weight 1514 and molecular formula C69H66N18O13S5; which is obtained by fermentation of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269). The invention includes all stereoisomeric forms and all tautomeric forms of the compound PM181104 and pharmaceutically acceptable salts and derivatives such as esters and ethers. The present invention further relates to processes for the production of the novel antibacterial compound(s), to the production of the microorganism belonging to Kocuria species (ZMA B-1/MTCC 5269), and to pharmaceutical compositions containing the novel compound(s) as an active ingredient and its/their use in medicines for treatment and prevention of diseases caused by bacterial infections.